$32.76
0.08[0.24%]
Last update: 11:21AM Get Real Time Here
Arvinas
(NASDAQ:ARVN)Latest News for Arvinas Stock (NASDAQ:ARVN)
Arvinas Stock (NASDAQ: ARVN)
Categories: All
Friday, May 17, 2024
Thursday, May 16, 2024
Wednesday, May 15, 2024
Thursday, May 09, 2024
Wednesday, May 08, 2024
- Wedbush Reiterates Outperform on Arvinas, Maintains $57 Price TargetBenzinga Newsdesk - May 8, 2024, 10:16AM
- Stifel Maintains Buy on Arvinas, Lowers Price Target to $68Benzinga Newsdesk - May 8, 2024, 9:09AM
- HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $87 Price TargetBenzinga Newsdesk - May 8, 2024, 8:53AM
Tuesday, May 07, 2024
- Arvinas's Cash, Cash Equivalents and Marketable Securities Position As of March 31, 2024 Were $1.2B Expected To Provide Cash Runway Into 2027Benzinga Newsdesk - May 7, 2024, 7:30AM
- Arvinas Q1 2024 GAAP EPS $(0.97) Beats $(1.38) Estimate, Sales $25.300M Miss $34.838M EstimateBenzinga Newsdesk - May 7, 2024, 7:29AM
Monday, April 15, 2024
Friday, April 12, 2024
Thursday, April 11, 2024
- Arvinas shares are trading higher after the company entered a license agreement with Novartis for the development and commercialization of ARV-766 in prostate cancer treatment.Benzinga Newsdesk - Apr 11, 2024, 7:25AM
- Arvinas Enters Exclusive Strategic License Agreement With Novartis; Arvinas To Receive $150M Upfront Payment & Up To $1.01B In MilestonesBenzinga Newsdesk - Apr 11, 2024, 7:22AM
Monday, March 25, 2024
Friday, March 01, 2024
Thursday, February 29, 2024
Wednesday, February 28, 2024
- HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $90 Price TargetBenzinga Newsdesk - Feb 28, 2024, 12:25PM
- BMO Capital Maintains Outperform on Arvinas, Raises Price Target to $90Benzinga Newsdesk - Feb 28, 2024, 9:05AM
- Navigating 7 Analyst Ratings For ArvinasBenzinga Insights - Feb 28, 2024, 8:01AM
- Wedbush Maintains Outperform on Arvinas, Raises Price Target to $59Benzinga Newsdesk - Feb 28, 2024, 7:54AM
- Oppenheimer Reiterates Outperform on Arvinas, Lowers Price Target to $80Benzinga Newsdesk - Feb 28, 2024, 7:34AM
Tuesday, February 27, 2024
Tuesday, February 20, 2024
- Arvinas Announces Chief Financial Officer Transition; Randy Teel, Ph.D. To Assume The Role Of Interim Chief Financial Officer; Sean Cassidy Leaving As Of February 29, 2024Benzinga Newsdesk - Feb 20, 2024, 4:44PM
- Arvinas Has Dosed The First Subject In Its Phase 1 Trial Of ARV-102, In Development To Treat Neurodegenerative DiseasesBenzinga Newsdesk - Feb 20, 2024, 7:13AM
Wednesday, February 14, 2024
- Citigroup Downgrades Arvinas to Neutral, Raises Price Target to $55Benzinga Newsdesk - Feb 14, 2024, 8:35AM
- Carrick Therapeutics Announces First Patient Dosed In Phase 1b/2 Clinical Trial Of Samuraciclib In Combination With Vepdegestrant In Patients With Advanced Breast CancerBenzinga Newsdesk - Feb 14, 2024, 8:05AM
Friday, February 09, 2024
Tuesday, February 06, 2024
Thursday, February 01, 2024
- Arvinas shares are trading higher after Goldman Sachs initiated coverage on the stock with a Buy rating and $70 price target.Benzinga Newsdesk - Feb 1, 2024, 11:15AM
- Eaton Posts Strong Results, Joins Ferrari, Boot Barn And Other Big Stocks Moving Higher On ThursdayAvi Kapoor - Feb 1, 2024, 10:46AM
- Forecasting The Future: 6 Analyst Projections For ArvinasBenzinga Insights - Feb 1, 2024, 8:00AM
- Goldman Sachs Initiates Coverage On Arvinas with Buy Rating, Announces Price Target of $70Benzinga Newsdesk - Feb 1, 2024, 7:04AM
Monday, January 08, 2024
Tuesday, December 19, 2023
Friday, December 08, 2023
Wednesday, December 06, 2023
- Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionLisa Levin - Dec 6, 2023, 2:43PM
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Dec 6, 2023, 12:31PM
- Jefferies Upgrades Arvinas to Buy, Raises Price Target to $40Benzinga Newsdesk - Dec 6, 2023, 11:08AM
- Arvinas shares are trading higher after the company and Pfizer announced interim data from the Phase 1b trial of Vepdegestrant in combination with Palbociclib.Benzinga Newsdesk - Dec 6, 2023, 11:06AM
- THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On WednesdayLisa Levin - Dec 6, 2023, 10:48AM
- Arvinas, Pfizer Plan To Broaden Development Of Breast Cancer CandidateVandana Singh - Dec 6, 2023, 8:50AM